Soligenix, Inc. (SNGX) News

Soligenix, Inc. (SNGX): $0.43

-0.01 (-2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SNGX News Items

SNGX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SNGX News Highlights

  • For SNGX, its 30 day story count is now at 2.
  • Over the past 1 day, the trend for SNGX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BIO, RARE and STAR are the most mentioned tickers in articles about SNGX.

Latest SNGX News From Around the Web

Below are the latest news stories about Soligenix Inc that investors may wish to consider to help them evaluate SNGX as an investment opportunity.

Soligenix (SNGX) Receives a Hold from Dawson James

Dawson James analyst Jason Kolbert maintained a Hold rating on Soligenix (SNGX – Research Report) on February 2. The company's shares closed last Tuesday at $0.62, close to its 52-week low of $0.58. According to TipRanks.com, Kolbert is a 3-star analyst with an average return of 2.3% and a 39.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Hold analyst consensus rating for Soligenix.

Christine Brown on TipRanks | February 9, 2022

Soligenix to Present at the 2022 BIO CEO & Investor Conference

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the BIO CEO & Investor Conference taking place February 14-17, 2022. The presentation will be available to registered conference attendees for on-demand vie

Yahoo | February 8, 2022

SNGX: Multiple Milestones Ahead in 2022…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Multiple Milestones Ahead in 2022 Soligenix, Inc. (NASDAQ:SNGX) has a number of important milestones and events ahead in 2022 as the company continues to develop its pipeline of specialized biotherapeutics and public health solutions. HyBryte™ Soligenix completed a Phase 3 clinical trial of HyBryte™ (SGX301,

Yahoo | January 13, 2022

Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)

New York, New York--(Newsfile Corp. - January 12, 2022) - PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, issued a corporate update this week with good news for their shareholders. Despite supply-chain delays in receiving the active pharmaceutical ingredient for SGX301, aka HyBryte™, the company is still on track to file a new drug application with the FDA in the latter half of 2022. HyBryte™ is an early-stage treatment for ...

Yahoo | January 12, 2022

Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.

Yahoo | January 10, 2022

Soligenix to Present at Upcoming Investor Conferences

PRINCETON, N.J., Jan. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,

Business Insider Markets | January 6, 2022

Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that dusquetide is effective at reducing tumor size in nonclinical xenograft models. Recent studies, recapitulating results from previously published studies, have confirmed the efficacy of dusquetide as a stand-alone and combination anti-tumor therapy, with radiation, chem

Yahoo | January 4, 2022

Reviewing Rani Therapeutics (NASDAQ:RANI) and Soligenix (NASDAQ:SNGX)

Rani Therapeutics (NASDAQ:RANI) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Rani Therapeutics and Soligenix, […]

Dakota Financial News | December 24, 2021

Short Interest in Soligenix, Inc. (NASDAQ:SNGX) Expands By 19.8%

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 1,210,000 shares, an increase of 19.8% from the November 15th total of 1,010,000 shares. Based on an average trading volume of 1,690,000 shares, the days-to-cover ratio is presently 0.7 days. SNGX [] The post Short Interest in Soligenix, Inc. (NASDAQ:SNGX) Expands By 19.8% appeared first on ETF Daily News .

ETF Daily News | December 22, 2021

Reviewing Soligenix (NASDAQ:SNGX) & CURE Pharmaceutical (OTCMKTS:CURR)

Soligenix (NASDAQ:SNGX) and CURE Pharmaceutical (OTCMKTS:CURR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability. Profitability This table compares Soligenix and CURE Pharmaceuticals net margins, return on equity and return on []

Dakota Financial News | December 20, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8187 seconds.